This advanced phenotype is prevented by rescuing CEACAM1 in the liver [108], providing further in vivo demonstration of the critical role that CEACAM1-dependent insulin clearance pathways play in the pathogenesis of hepatic insulin resistance and NAFLD/NASH. Here, CEACAM1 is linked to metabolic dysfunction-associated steatohepatitis.